This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 18 and 85
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This clinical pilot study will test the hypothesis that systemic low-dose IL-2 therapy significantly enhances the immunologic efficacy of a vaccine comprising melanoma peptides plus GM-CSF-in-adjuvant.

Provided treatments

  • Drug: low-dose IL-2
  • Biological: melanoma vaccine
Tris trial is registered with FDA with number: NCT00928902. The sponsor of the trial is University of Virginia and it is looking for 41 volunteers for the current phase.
Official trial title:
Pilot Phase II Trial for the Evaluation of the Effect of Systemic Low-dose IL-2 on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant, in Patients With High Risk Melanoma